

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1450 Alexandris, Vignia 22313-1450 www.usple.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,647		07/30/2001	Kenichi Arai	2001-0531A	1900
513	7590	09/10/2003			
		LIND & PONACK, I	EXAMINER		
2033 K STR SUITE 800	EET N	1. W.	YAEN, CHRISTOPHER H		
WASHING	ΓON, Ε	OC 20006-1021		ART UNIT	PAPER NUMBER
				1642	1/
				DATE MAILED: 09/10/2003	16

Please find below and/or attached an Office communication concerning this application or proceeding.

		Amultant	n No	Applicant(s)					
•^		Application	on No.	Applicant(s)					
	Office Action Commence	09/830,64	17 	ARAI ET AL.					
	Offic Action Summary	Examiner		Art Unit					
*		Christoph		1642					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status									
1)⊠	Responsive to communication(s) filed on 2	28 February 20	<u>003</u> .						
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠	This action is	non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims									
4)🛛	Claim(s) <u>1,3,5-7 and 10-30</u> is/are pending	in the applicat	on.						
4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.									
6)⊠	6)⊠ Claim(s) <u>12,13,25 and 26</u> is/are rejected.								
7) Claim(s) is/are objected to.									
8)[	8) Claim(s) are subject to restriction and/or election requirement.								
Application Papers									
9) The specification is objected to by the Examiner.									
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
-	a)⊠ All b)□ Some * c)□ None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
	cknowledgment is made of a claim for dome		Ť		plication).				
_a)	☐ The translation of the foreign language	provisional ap	plication has	been received.	, ,				
Attachment(s)									
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s		5) Notice of	v Summary (PTO-413) Paper No(s). f Informal Patent Application (PTO-15					
.S. Patent and Tra PTOL-326 (Re		e Action Summa		Part of Pap	er No. 16				

Application/Control Number: 09/830,647

Art Unit: 1642

#### **DETAILED ACTION**

- Applicant's request for reconsideration of the finality of the rejection of the last
   Office action is persuasive and, therefore, the finality of that action is withdrawn.
- 2. The after final amendment filed 2/28/2003 (paper no. 15) is acknowledged and entered into the record. Accordingly, claims 5-7, and 20 are amended.
- 3. Claims 1,3,5-7, and 10-30 are pending and examined on the merits.

# **New Arguments**

# Claim Objections

4. Applicant is advised that should claims 1 and 3 be found allowable, claims 18 and 19 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

## Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein

Application/Control Number: 09/830,647

Art Unit: 1642

were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 12-13 and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kellen J *et al* (EMBL/GenBank/DDBJ Database submitted June 1998) or Waterston R *et al* (EMBL/GenBank/DDBJ Database submitted June 1998) in view of Harlow *et al* (Antibodies, A Laboratory Manual, Chapter 5, page 76, 1988).

Claims are drawn to an isolated antibody that binds specifically to SEQ ID Nos. 1 and 2.

Kellen J et al and Waterston R et al disclosed the sequence of which was publicly available as of June 1998. Harlow et al teaches that antibodies can be made to proteins with as little as 6 amino acids.

Therefore, it would have been *prima facie* obvious at the time the invention was made to one of ordinary skill in the art to make antibodies against the polypeptides of Kellen J *et al* and Waterston R et al. for the purposes of isolating and detecting the expressed antigen. Further, one would expect that polyclonal antibodies would cross-react with the polypeptides of SEQ ID NO: 1 and 2 because the antigen of Kellen J *et al* and Waterston R et al. indicates a 65% identity match to the polypeptide of SEQ ID NO:1 and 2. The antibodies produced would cross react and bind to an epitope of the Kellen R *et al* or Waterston *et al* protein because the smallest synthetic peptides that

Application/Control Number: 09/830,647

Art Unit: 1642

will consistently elicit antibodies that bind to the original protein are 6 residues in length (Harlow *et al.*, Antibodies, A Laboratory Manual, Chapter 5, page 76, 1988).

# Conclusion

8. Claims 12-13 and 25-26 are rejected. Claims 1,3,5-7, 10-11, 14-24, and 27-30 are free of the prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen Art Unit 1642 August 25, 2003 ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600